PADDINGTON

Pharmacodynamic Approaches to Demonstration of Disease-Modification in Huntington’s Disease by SEN0014196

Coordinatore	SIENA BIOTECH SPA    more  Organization address address: Via Banchi di Sotto 34 city: SIENA postcode: 53100 contact info Titolo: Dr. Nome: Enrica Cognome: Diodato Email: send email Telefono: +39 0577 381454 Fax: +39 0577 381208
Nazionalità Coordinatore	Italy [IT]
Sito del progetto	http://www.paddingtonproject.eu
Totale costo	8˙589˙885 €
EC contributo	5˙816˙313 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2010-single-stage
Funding Scheme	CP-FP
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-07-01   -   2013-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	SIENA BIOTECH SPA  Organization address address: Via Banchi di Sotto 34 city: SIENA postcode: 53100 contact info Titolo: Dr. Nome: Enrica Cognome: Diodato Email: send email Telefono: +39 0577 381454 Fax: +39 0577 381208	IT (SIENA)	coordinator	1˙540˙673.80
2	UNIVERSITY COLLEGE LONDON  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Ms. Nome: Greta Cognome: Borg-Carbott Email: send email Telefono: +44 20 3108 3033 Fax: +44 20 7813 2849	UK (LONDON)	participant	2˙001˙045.20
3	UNIVERSITAET ULM  Organization address address: HELMHOLTZSTRASSE 16 city: ULM postcode: 89081 contact info Titolo: Mr. Nome: Frank Cognome: Gleixner Email: send email Telefono: +49 731 500 66397 Fax: +49 731 500 66392	DE (ULM)	participant	1˙104˙681.20
4	KCR SA  Organization address address: UL. POSTEPU 6 city: WARSZAWA postcode: 02 676 contact info Titolo: Dr. Nome: Agnieszka Cognome: Felicja?czuk Email: send email Telefono: +48 22 31 3 13 31 Fax: +48 22 313 13 14	PL (WARSZAWA)	participant	916˙669.90
5	LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE  Organization address address: KEPPEL STREET city: LONDON postcode: WC1E7HT contact info Titolo: Ms. Nome: Dawn Cognome: Carpenter Email: send email Telefono: 442079000000 Fax: 442076000000	UK (LONDON)	participant	253˙243.60

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The Consortium will undertake clinical research activities aimed at ascertaining feasibility of a range of pharmacodynamic readouts for use in the clinical development of SEN0014196 to demonstrate the disease-modifying properties of the compound in Huntington’s Disease. SEN0014196 is a novel and selective SirT1 inhibitor, currently in Phase I clinical development, and enjoys Orphan Status in the EU as of September 2, 2009. A multi-factorial approach will be used, including assessment of both novel and compound-specific measures of molecular action as well as previously identified predictors of disease progression. The translational approaches addressed by this project are instrumental in the progression of SEN0014196 to clinical proof-of-concept and, if successful, will play a pivotal role in patient stratification and outcomes research. The Consortium will comprise four partners, all with a proven track-record in Research and Development in the Huntington’s Disease area. All Partners are based within the EU.'

Introduzione (Teaser)

Huntington's disease (HD) is a devastating progressive disorder. Delaying disease onset requires novel targeted interventions early on in life.